Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview

Tonix Pharmaceuticals Holding

07/08/2026 17:58

Tonix Pharmaceuticals Holding Corp. TNXP.OQ TNXP.O is expected to  show a rise in quarterly revenue when it reports  results on August 10 for the period ending June 30 2026
The Berkeley Heights New Jersey-based  company is expected to report a 286.5% increase in revenue to $7.723 million from $2 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Tonix Pharmaceuticals Holding Corp. is for a loss of $2.70 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp. is $34.00, about 191.8% above its last closing price of $11.65
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-2.46
-2.43
-2.93
Missed
-20.4
Dec. 31 2026
-3.01
-3.19
-3.98
Missed
-24.8
Sep. 30 2025
-3.35
-3.58
-3.59
Missed
-0.1​
Jun. 30 2025
-3.44
-3.21
-3.86
Missed
-20.1
​​Mar. 31 2025
-3.30
-3.23
-2.84
Beat
12.1
Dec. 31 2024
-6.23
-3.87 hundred
-9.77
Beat
97.5​
Sep. 30 2024
-67.29
-2.93 hundred
-23.00
Beat
92.2
Jun. 30 2024
-1.23 hundred
-3.27 hundred
-1.93 thousand
Missed
-489
This summary was machine generated August 7 at 16:58 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)